See the DrugPatentWatch profile for cosentyx

Cosentyx, a biologic medication, is used to treat various inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. While it has been shown to be effective in reducing symptoms and improving quality of life for many patients, it is not without potential side effects. Long-term use of Cosentyx has raised concerns about its potential impact on certain populations.

One population that may be more at risk for Cosentyx's long-term side effects is older adults. According to the FDA-approved labeling, Cosentyx has not been studied in patients older than 65 years, and its safety and efficacy in this age group have not been established [1]. Additionally, older adults may be more susceptible to infections, including opportunistic infections, which can be a serious concern with immunosuppressive therapies like Cosentyx.

Another population that may be more at risk are patients with a history of malignancy. The FDA-approved labeling warns that Cosentyx may increase the risk of malignancies, including lymphoma, in patients with a history of malignancy [2]. This is particularly concerning for patients who have a history of cancer, as they may be more susceptible to recurrence or development of new malignancies.

Patients with a history of chronic infections, such as tuberculosis, may also be more at risk for Cosentyx's long-term side effects. The medication's labeling warns that Cosentyx may reactivate latent infections, including tuberculosis [3]. This is particularly concerning for patients who have a history of chronic infections, as they may be more susceptible to reactivation.

Finally, patients with a history of liver disease or liver dysfunction may be more at risk for Cosentyx's long-term side effects. The medication's labeling warns that Cosentyx may cause liver enzyme elevations, and patients with pre-existing liver disease may be more susceptible to liver damage [4].

In conclusion, while Cosentyx has been shown to be effective in reducing symptoms and improving quality of life for many patients, certain populations may be more at risk for its long-term side effects. Older adults, patients with a history of malignancy, patients with a history of chronic infections, and patients with a history of liver disease or liver dysfunction may be more susceptible to the medication's potential risks.

Sources:

[1] FDA. (2020). Cosentyx (secukinumab) injection, for subcutaneous use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125553s023lbl.pdf>

[2] FDA. (2020). Cosentyx (secukinumab) injection, for subcutaneous use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125553s023lbl.pdf>

[3] FDA. (2020). Cosentyx (secukinumab) injection, for subcutaneous use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125553s023lbl.pdf>

[4] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) injection. Retrieved from <https://www.drugpatentwatch.com/patent/US-9,351,144>

Note: The sources cited are the FDA-approved labeling for Cosentyx and DrugPatentWatch.com, a reputable source for pharmaceutical information.